149 related articles for article (PubMed ID: 29258557)
1. Moloney leukemia virus 10 (MOV10) inhibits the degradation of APOBEC3G through interference with the Vif-mediated ubiquitin-proteasome pathway.
Chen C; Ma X; Hu Q; Li X; Huang F; Zhang J; Pan T; Xia J; Liu C; Zhang H
Retrovirology; 2017 Dec; 14(1):56. PubMed ID: 29258557
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
[TBL] [Abstract][Full Text] [Related]
3. The Disassociation of A3G-Related HIV-1 cDNA G-to-A Hypermutation to Viral Infectivity.
Martin J; Chen X; Jia X; Shao Q; Liu B
Viruses; 2024 May; 16(5):. PubMed ID: 38793610
[TBL] [Abstract][Full Text] [Related]
4. Design of Vif-Derived Peptide Inhibitors with Anti-HIV-1 Activity by Interrupting Vif-CBFβ Interaction.
Gai Y; Duan S; Wang S; Liu K; Yu X; Yang C; Li G; Zhou Y; Yu B; Wu J; Wang C; Yu X
Viruses; 2024 Mar; 16(4):. PubMed ID: 38675833
[TBL] [Abstract][Full Text] [Related]
5. Endogenous MOV10 inhibits the retrotransposition of endogenous retroelements but not the replication of exogenous retroviruses.
Arjan-Odedra S; Swanson CM; Sherer NM; Wolinsky SM; Malim MH
Retrovirology; 2012 Jun; 9():53. PubMed ID: 22727223
[TBL] [Abstract][Full Text] [Related]
6. UPF1 is crucial for the infectivity of human immunodeficiency virus type 1 progeny virions.
Serquiña AK; Das SR; Popova E; Ojelabi OA; Roy CK; Göttlinger HG
J Virol; 2013 Aug; 87(16):8853-61. PubMed ID: 23785196
[TBL] [Abstract][Full Text] [Related]
7. The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication.
Wang X; Ao Z; Chen L; Kobinger G; Peng J; Yao X
J Virol; 2012 Apr; 86(7):3777-86. PubMed ID: 22301159
[TBL] [Abstract][Full Text] [Related]
8. The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells.
Norman JM; Mashiba M; McNamara LA; Onafuwa-Nuga A; Chiari-Fort E; Shen W; Collins KL
Nat Immunol; 2011 Aug; 12(10):975-83. PubMed ID: 21874023
[TBL] [Abstract][Full Text] [Related]
9. Requirements for nucleocapsid-mediated regulation of reverse transcription during the late steps of HIV-1 assembly.
Racine PJ; Chamontin C; de Rocquigny H; Bernacchi S; Paillart JC; Mougel M
Sci Rep; 2016 Jun; 6():27536. PubMed ID: 27273064
[TBL] [Abstract][Full Text] [Related]
10. Characterization of an A3G-Vif
Kaake RM; Echeverria I; Kim SJ; Von Dollen J; Chesarino NM; Feng Y; Yu C; Ta H; Chelico L; Huang L; Gross J; Sali A; Krogan NJ
Mol Cell Proteomics; 2021; 20():100132. PubMed ID: 34389466
[TBL] [Abstract][Full Text] [Related]
11. Deep sequencing of HIV-1 reverse transcripts reveals the multifaceted antiviral functions of APOBEC3G.
Pollpeter D; Parsons M; Sobala AE; Coxhead S; Lang RD; Bruns AM; Papaioannou S; McDonnell JM; Apolonia L; Chowdhury JA; Horvath CM; Malim MH
Nat Microbiol; 2018 Feb; 3(2):220-233. PubMed ID: 29158605
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking analysis of RN18 and VEC5 in A3G-Vif inhibition.
Sinha C; Nischal A; Pant KK; Bandaru S; Nayarisseri A; Khattri S
Bioinformation; 2014; 10(10):611-6. PubMed ID: 25489169
[TBL] [Abstract][Full Text] [Related]
13. High-speed atomic force microscopy directly visualizes conformational dynamics of the HIV Vif protein in complex with three host proteins.
Pan Y; Shlyakhtenko LS; Lyubchenko YL
J Biol Chem; 2020 Aug; 295(34):11995-12001. PubMed ID: 32587092
[TBL] [Abstract][Full Text] [Related]
14. Insights into DNA substrate selection by APOBEC3G from structural, biochemical, and functional studies.
Ziegler SJ; Liu C; Landau M; Buzovetsky O; Desimmie BA; Zhao Q; Sasaki T; Burdick RC; Pathak VK; Anderson KS; Xiong Y
PLoS One; 2018; 13(3):e0195048. PubMed ID: 29596531
[TBL] [Abstract][Full Text] [Related]
15. Development of Lentiviral Vectors for HIV-1 Gene Therapy with Vif-Resistant APOBEC3G.
Delviks-Frankenberry KA; Ackerman D; Timberlake ND; Hamscher M; Nikolaitchik OA; Hu WS; Torbett BE; Pathak VK
Mol Ther Nucleic Acids; 2019 Dec; 18():1023-1038. PubMed ID: 31778955
[TBL] [Abstract][Full Text] [Related]
16. Selection and characterization of aptamers targeting the Vif-CBFβ-ELOB-ELOC-CUL5 complex.
Kumagai K; Kamba K; Suzuki T; Sekikawa Y; Yuki C; Hamada M; Nagata K; Takaori-Kondo A; Wan L; Katahira M; Nagata T; Sakamoto T
J Biochem; 2024 May; ():. PubMed ID: 38740386
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Vif Triggers Cell Cycle Arrest by Degrading Cellular PPP2R5 Phospho-regulators.
Salamango DJ; Ikeda T; Moghadasi SA; Wang J; McCann JL; Serebrenik AA; Ebrahimi D; Jarvis MC; Brown WL; Harris RS
Cell Rep; 2019 Oct; 29(5):1057-1065.e4. PubMed ID: 31665623
[TBL] [Abstract][Full Text] [Related]
18. HIV restriction factor APOBEC3G binds in multiple steps and conformations to search and deaminate single-stranded DNA.
Morse M; Naufer MN; Feng Y; Chelico L; Rouzina I; Williams MC
Elife; 2019 Dec; 8():. PubMed ID: 31850845
[TBL] [Abstract][Full Text] [Related]
19. The MOV10 RNA helicase is a dosage-dependent host restriction factor for LINE1 retrotransposition in mice.
Guan Y; Gao H; Leu NA; Vourekas A; Alexiou P; Maragkakis M; Kang Z; Mourelatos Z; Liang G; Wang PJ
PLoS Genet; 2023 May; 19(5):e1010566. PubMed ID: 37126510
[TBL] [Abstract][Full Text] [Related]
20. Cellular RNA helicases and HIV-1: insights from genome-wide, proteomic, and molecular studies.
Chen CY; Liu X; Boris-Lawrie K; Sharma A; Jeang KT
Virus Res; 2013 Feb; 171(2):357-65. PubMed ID: 22814432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
